日韩av大片在线观看欧美成人不卡|午夜先锋看片|中国女人18毛片水多|免费xx高潮喷水|国产大片美女av|丰满老熟妇好大bbbbbbbbbbb|人妻上司四区|japanese人妻少妇乱中文|少妇做爰喷水高潮受不了|美女人妻被颜射的视频,亚洲国产精品久久艾草一,俄罗斯6一一11萝裸体自慰,午夜三级理论在线观看无码

TIGIT （T cell immunoglobulin and ITIM domain） is an inhibitory receptor expressed on lymphocytes, including natural killer （NK） cells and various subsets of T cells such as CD4+ T cells, CD8+ T cells, and regulatory T cells. It was discovered in 2009 through genome-wide analysis aiming to identify proteins containing domain structures typical for immunomodulatory receptors. TIGIT consists of one extracellular immunoglobulin variable domain, a type I transmembrane domain, and a short intracellular domain with one immunoreceptor tyrosine-based inhibitory motif （ITIM） and one immunoglobulin tyrosine tail （ITT）-like motif. Its main ligand is CD155, also known as poliovirus receptor （PVR）, but it can also bind to CD112 and CD113 with lower affinity. TIGIT plays a significant role in down-regulating T cell and NK cell functions by interacting with these ligands expressed on antigen-presenting cells or tumor cells. This interaction inhibits immune cell responses at multiple steps of the cancer-immunity cycle, such as impairing T cell priming by dendritic cells, preventing tumor cell killing by NK cells and cytotoxic T cells, and enhancing the immune suppressive activity of regulatory T cells. Therefore, TIGIT has emerged as a major target in cancer immunotherapy. Several monoclonal antibodies that block the inhibitory activity of human TIGIT have been developed, and clinical trials are ongoing to investigate TIGIT blockade as a monotherapy or in combination with anti-PD1/PD-L1 antibodies for the treatment of patients with advanced solid malignancies.